Bartonella is not rare. A 2014 study at Duke University and North Carolina State University found Bartonella DNA in 28% of veterinary workers — people in regular contact with cats and dogs. A significant proportion of people with chronic Lyme-like illness test positive for Bartonella at specialist labs. Yet mainstream medicine recognises bartonellosis almost exclusively as a self-limiting condition from a cat scratch. The reality is considerably more complex.
If you've found your way to this page, there's a fair chance you already suspect Bartonella — maybe a specialist test came back positive and your own doctor waved it away, or maybe you're here because the anxiety, the rage, the symptoms that feel almost chemical don't match anything you've been told you have.
That gap — between what your body is doing and what the system is willing to see — is exhausting on its own. This page won't diagnose you. But it should give you language and context sharp enough to ask better questions, and to stop doubting what you already sense.
For a long time the symptoms hardest to say out loud weren't the joint pain or the fatigue — they were the ones in my head. Waves of anxiety out of nowhere. The feeling that my own mind had turned against me.
From everything I've read since, that pattern — neuropsychiatric symptoms riding alongside a tick-borne infection — is far more common than people are told, and far too rarely taken seriously. I'm not a doctor, and this isn't a diagnosis. But if any of it sounds like your experience: it has a name, and you are not imagining it.
A stealth pathogen — designed to hide
Bartonella is not hard to miss by accident. It is well-adapted to evading detection at every level: from the immune response to standard laboratory testing.
Bartonella hides inside red blood cells and endothelial cells. Standard blood cultures look for bacteria floating freely in plasma — Bartonella is not there. Special enrichment culture media are required to detect it. A standard culture negative for Bartonella tells you almost nothing about whether the infection is present.
Even when Bartonella does circulate in the bloodstream, it does so intermittently. A blood draw on the wrong day may show nothing. Galaxy Diagnostics addresses this by using an enrichment medium to amplify bacterial load from a blood sample before running PCR — dramatically improving detection compared to direct PCR testing.
Bartonella actively modulates the host immune response. It suppresses inflammatory signals that would normally alert the immune system. This is why many infected people show completely normal inflammatory markers on routine bloodwork — and why standard antibody tests have poor sensitivity. The bacteria can be present and active while the immune response remains weak or delayed.
Medical education presents Bartonella almost exclusively as a self-limiting condition in children. A doctor who learned this is not looking for it as a cause of treatment-resistant depression in adults, unexplained rage episodes in teenagers, or culture-negative endocarditis. The narrow framing systematically excludes the broader clinical spectrum — and leaves countless patients without answers.
How to detect it — and what standard tests miss
Standard hospital laboratory testing for Bartonella is largely inadequate for chronic infection. A negative result at a standard lab cannot rule out infection. For chronic illness patients — particularly those with Lyme — specialist laboratory testing is the appropriate approach.
Given the limitations of all available Bartonella tests, clinical diagnosis remains important. A pattern of cycling neuropsychiatric symptoms, burning foot pain, unusual skin streaks, lymph node tenderness, and a history of tick bites, animal contact, or flea exposure — taken together — can justify a treatment trial even without a confirmed positive test. Many Lyme-literate physicians approach Bartonella diagnosis the same way they approach Lyme: by assessing the whole clinical picture, not waiting for a definitive lab result that may never come.
Treatment — what works and what doesn't
Bartonella treatment is more complex than treating standard acute bacterial infections. Its intracellular nature means antibiotics must penetrate cells to be effective — not all antibiotics do this. And because Bartonella can establish chronic infection, short treatment courses may suppress but not clear the infection, leading to relapse.
Rifampin (rifampicin) combined with doxycycline or azithromycin is the most commonly used combination in Lyme-literate practice. Rifampin has excellent intracellular penetration and is effective against Bartonella. Treatment duration is typically 4–6 weeks minimum for chronic infection; many ILADS clinicians treat for significantly longer depending on clinical response.
Bartonella treatment can provoke a Herxheimer reaction as bacteria die and release inflammatory compounds. This can temporarily worsen neuropsychiatric symptoms — increased anxiety, rage, or cognitive impairment. This reaction, unpleasant as it is, can itself be a diagnostic signal confirming active infection. Careful management of the die-off response is part of treatment.
Bartonella can relapse after antibiotic courses end, particularly in immunocompromised patients or those co-infected with Lyme. The cyclic nature of the infection means monitoring for several months after treatment completion is important. Some patients require multiple treatment courses before achieving sustained improvement.
The mainstream guidance for cat scratch disease — often no antibiotics at all, or a short course of azithromycin — is appropriate for a healthy person with mild lymphadenopathy who will recover on their own. It is not appropriate for chronic Bartonella infection with neurological involvement, co-infection with Lyme disease, or any patient whose immune system is struggling. These are different clinical situations that require different treatment approaches.
Bartonella and Lyme — when they occur together
Bartonella and Lyme disease co-infection is common in tick-borne illness patients. The presence of both infections simultaneously changes the clinical picture in important ways — and has direct implications for treatment.
Borrelia and Bartonella respond to different antibiotics. Doxycycline is a cornerstone of Lyme treatment but is only moderately effective against Bartonella. Rifampin is effective against Bartonella but not Lyme. A treatment protocol that adequately addresses Lyme may not touch Bartonella — and vice versa. This is why some patients improve on standard Lyme treatment and then plateau or relapse: the Bartonella co-infection is not being addressed.
In Lyme-Bartonella co-infection, the neuropsychiatric component is often driven more by Bartonella than by Borrelia. Research suggests that Lyme with Bartonella co-infection produces psychiatric syndromes more consistently than Lyme alone. If a patient has significant psychiatric or neurological symptoms that are not responding to Lyme-targeted treatment, adding Bartonella-targeted antibiotics sometimes produces dramatic improvement. This pattern — improvement of psychiatric symptoms with antibiotic treatment — is itself diagnostically informative.
Your next step
Sources & further reading
- Breitschwerdt EB et al. — Bartonella-associated cutaneous lesions (BACL) in people with neuropsychiatric symptoms. Pathogens, 2020
- Breitschwerdt EB — Bartonellosis: One Health Perspectives for an Emerging Infectious Disease. ILAR Journal, 2014
- Schaller JL, Burkland GA, Langhoff PJ — Do Bartonella Infections Cause Agitation, Panic Disorder, and Treatment-Resistant Depression? MedGenMed, 2007
- AVMA — Bartonellosis: A zoonosis hidden in plain sight, 2021
- Galaxy Diagnostics — From Cat Scratch Disease to Bartonellosis
- IGeneX — Overview of Bartonella species and testing
- Cameron D — Bartonella and Lyme Disease: Symptoms and Treatment, danielcameronmd.com
- LymeDisease.org — The Bartonella clue hidden in plain sight, 2026
- Human Bartonellosis: An Underappreciated Public Health Problem? PMC6630881
Last updated: April 2026